RxDoctor Payments Data

Honore Gormley, APRN

Nurse Practitioner · Meriden, CTNPI 1487663118

Payments from drug & device makers

$3,725in general payments, 2019–2025

Across 186 payments — averaging $20.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$847
  • AstraZeneca$590
  • Boehringer Ingelheim$293
  • Takeda Pharmaceuticals U.S.A., Inc.$286
  • Regeneron Healthcare Solutions, Inc.$242
  • Amgen$219
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$3,725100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,725 in reported general payments places this provider in the 90th percentile of 1,162 nurse practitioner providers in Connecticut.

See all nurse practitioner providers in Connecticut

Medicare billing

Part B allowed, 2024
$19,871
Medicare patients
143
Services billed
240

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter236$175,189
EliquisApixaban24$15,512
Breztri AerosphereBudesonide/Glycopyr/Formoterol21$15,186
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr22$12,971
Stiolto RespimatTiotropium Br/Olodaterol Hcl12$11,653
Spiriva HandihalerTiotropium Bromide17$11,562
Breo ElliptaFluticasone/Vilanterol22$10,534
SymbicortBudesonide/Formoterol Fumarate22$8,455
Spiriva RespimatTiotropium Bromide15$7,709
Wixela InhubFluticasone Propion/Salmeterol23$3,627
Albuterol Sulfate HfaAlbuterol Sulfate128$2,506
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate17$2,366
Ventolin HfaAlbuterol Sulfate31$1,755
Prednisone68$226
Montelukast Sodium35$141

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$847$198,694280 claims
AstraZenecaBreztri Aerosphere, Symbicort$590$23,64143 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$293$19,36227 claims
PfizerEliquis$198$15,51224 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,162 nurse practitioner providers in Connecticut.

Other nurse practitioner in Meriden

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →